Plain-English translation of NCT06764095 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a combination of two drugs— and —to treat advanced bladder and ureter cancers that have spread to lymph nodes or other parts of the body. You would receive these medications by IV infusion every three weeks for at least 12 weeks, and then, if your cancer shrinks enough and you're healthy enough, you may have surgery to remove your bladder and/or ureter. After surgery, you may continue taking the medications.
Advanced bladder and ureter cancers are serious and difficult to treat. This trial is testing whether giving these two medications before surgery—rather than after—might help more patients respond well to treatment, have their cancer shrink significantly, and potentially improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic every 3 weeks to receive two IV medications (each taking about 30 minutes). You'll have blood and urine samples taken regularly and imaging scans (CT, PET, or MRI) to monitor your cancer. After at least 12 weeks of treatment, if your cancer responds well and you're a good surgical candidate, you would have surgery to remove your bladder and/or ureter. You may then continue the medications after surgery. Throughout the trial, you'll be followed with visits every 9 weeks initially, then every 12 weeks, for up to 5 years.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States